Reducing valproate use in women with epilepsy

Lancet Neurol. 2018 Jul;17(7):580-581. doi: 10.1016/S1474-4422(18)30172-8.

Authors

Reetta Kälviäinen¹, Sabine Straus², Jean-Michel Dogne³, Serge Bakchine⁴, Manuel Haas⁵

Affiliations

¹ Department of Neurology, University of Eastern Finland, Kuopio, Finland.
² Department of Policy and Regulatory Affairs, Medicines Evaluation Board, Utrecht, Netherlands.
³ Department of Pharmacy, University of Namur, Namur, Belgium.
⁴ Department of Neurology, Hôpital Maison Blanche, Reims, France.
⁵ Department of Evaluation, European Medicines Agency, London E14 5EU, UK. Electronic address: manuel.haas@ema.europa.eu.

PMID: 29914703
DOI: 10.1016/S1474-4422(18)30172-8

No abstract available

Publication types

Letter

MeSH terms

Abnormalities, Drug-Induced / prevention & control*
Adolescent
Adult
Anticonvulsants / adverse effects*
Drug Utilization
Epilepsy / drug therapy*
Female
Humans
Pharmacovigilance
Pregnancy
Risk Assessment
Valproic Acid / adverse effects*
Young Adult

Substances

Anticonvulsants
Valproic Acid